The U.S. FDA accelerated the approval of Tarlatamab-dlle (trade name Imdelltra) for the treatment of extensive small cell lung cancer on May 16, 2024, bringing new hope to patients who have progressed after platinum chemotherapy. This innovative bispecific T-cell adapter showed excellent efficacy in the DeLLphi-301 clinical trial, with an objective remission rate of 40% and a median remission duration of 9.7 months. The drug effectively activates the patient's own immune system to attack cancer cells by targeting DLL3 and CD3. It is worth noting that the Hong Kong Department of Health has also recently approved the registration of related new drugs for the treatment of diffuse small cell lung cancer, indicating Hong Kong's positive progress in integrating the field of cancer treatment with international standards. For patients and their families in need, the professional team of the Hong Kong United Cancer Centre (HKUOC) can provide detailed medical consultations to help formulate the most suitable personalized treatment plan and grasp the golden opportunity for treatment.
